Thrombophilia identified as a risk factor for thrombogenesis in cancer patients
Aim: to assess a rate and range of genetic and acquired thrombophilia in onco-gynecologic patients with ovarian cancer, uterine corpus cancer and cervical cancer.Materials and Мethods. A prospective controlled cohort non-randomized interventional study was conducted: within the years 2014 to 2020, t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2021-07-01
|
| Series: | Акушерство, гинекология и репродукция |
| Subjects: | |
| Online Access: | https://www.gynecology.su/jour/article/view/1003 |
| _version_ | 1826567074927869952 |
|---|---|
| author | A. V. Vorobev A. D. Makatsariya V. O. Bitsadze A. G. Solopova D. A. Ponomarev |
| author_facet | A. V. Vorobev A. D. Makatsariya V. O. Bitsadze A. G. Solopova D. A. Ponomarev |
| author_sort | A. V. Vorobev |
| collection | DOAJ |
| description | Aim: to assess a rate and range of genetic and acquired thrombophilia in onco-gynecologic patients with ovarian cancer, uterine corpus cancer and cervical cancer.Materials and Мethods. A prospective controlled cohort non-randomized interventional study was conducted: within the years 2014 to 2020, there were examined 546 women with genital malignancies, divided into 2 groups: group I – 155 cancer patients with former thrombosis, group II – 391 women with female genital cancer without former thrombotic complications. Control group consisted of 137 patients with benign female genital tumors. The spectrum of circulating APA was studied: antibodies to â2-glycoprotein I (â2-GPI), annexin V and prothrombin as well as genetic thrombophilia due to mutations genes encoding factor V Leiden, methylenetetrahydrofolate reductase (MTHFR) including polymorphism in genes for prothrombin, platelet glycoproteins and plasminogen activator inhibitor-1 (PAI-1).Results. It was found that frequency of circulating APA as well as incidence rate of genetic thrombophilia between cancer patients from group I vs. group II significantly differed: APA in group I vs. group II was 86 (55.5 %; p < 0.01) vs. 92 (23.5 %) compared to 7 (5.1 %) in control group. Genetic thrombophilia was dominated in group I by mutated MTHFR (92.9 %), polymorphismin PAI-1 (28.4 %) and platelet glycoprotein (44.5 %) that were significantly higher (p < 0.05) compared to group II and control group. Hence, it allows to suggest that such identified thrombophilia markers are largely associated with a risk of developing thrombotic complications.Conclusion. Detected high percentage of patients with circulating APA and genetic thrombophilia among cancer patients with former thromboembolic complications corroborate a role for genetic and acquired thrombophilia in developing pre-thrombotic condition. Detecting a range of circulating APA and genetic thrombophilia allows to identify patients who might be referred to a high risk of thrombogenesis and require to preventive application of anticoagulant therapy. |
| first_indexed | 2024-04-10T04:01:25Z |
| format | Article |
| id | doaj.art-3950284fcfb84626a7e9524185f9c5dd |
| institution | Directory Open Access Journal |
| issn | 2313-7347 2500-3194 |
| language | Russian |
| last_indexed | 2025-03-14T11:01:46Z |
| publishDate | 2021-07-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Акушерство, гинекология и репродукция |
| spelling | doaj.art-3950284fcfb84626a7e9524185f9c5dd2025-03-02T10:43:06ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942021-07-0115322823510.17749/2313-7347/ob.gyn.rep.2021.232648Thrombophilia identified as a risk factor for thrombogenesis in cancer patientsA. V. Vorobev0A. D. Makatsariya1V. O. Bitsadze2A. G. Solopova3D. A. Ponomarev4Sechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversityMaternity Hospital № 4 – Branch of Vinogradov City Clinical Hospital, Moscow Healthcare DepartmentAim: to assess a rate and range of genetic and acquired thrombophilia in onco-gynecologic patients with ovarian cancer, uterine corpus cancer and cervical cancer.Materials and Мethods. A prospective controlled cohort non-randomized interventional study was conducted: within the years 2014 to 2020, there were examined 546 women with genital malignancies, divided into 2 groups: group I – 155 cancer patients with former thrombosis, group II – 391 women with female genital cancer without former thrombotic complications. Control group consisted of 137 patients with benign female genital tumors. The spectrum of circulating APA was studied: antibodies to â2-glycoprotein I (â2-GPI), annexin V and prothrombin as well as genetic thrombophilia due to mutations genes encoding factor V Leiden, methylenetetrahydrofolate reductase (MTHFR) including polymorphism in genes for prothrombin, platelet glycoproteins and plasminogen activator inhibitor-1 (PAI-1).Results. It was found that frequency of circulating APA as well as incidence rate of genetic thrombophilia between cancer patients from group I vs. group II significantly differed: APA in group I vs. group II was 86 (55.5 %; p < 0.01) vs. 92 (23.5 %) compared to 7 (5.1 %) in control group. Genetic thrombophilia was dominated in group I by mutated MTHFR (92.9 %), polymorphismin PAI-1 (28.4 %) and platelet glycoprotein (44.5 %) that were significantly higher (p < 0.05) compared to group II and control group. Hence, it allows to suggest that such identified thrombophilia markers are largely associated with a risk of developing thrombotic complications.Conclusion. Detected high percentage of patients with circulating APA and genetic thrombophilia among cancer patients with former thromboembolic complications corroborate a role for genetic and acquired thrombophilia in developing pre-thrombotic condition. Detecting a range of circulating APA and genetic thrombophilia allows to identify patients who might be referred to a high risk of thrombogenesis and require to preventive application of anticoagulant therapy.https://www.gynecology.su/jour/article/view/1003genetic and acquired thrombophiliathrombotic complicationsanticoagulant therapycirculating antiphospholipid antibodiesapathrombosis risk factors |
| spellingShingle | A. V. Vorobev A. D. Makatsariya V. O. Bitsadze A. G. Solopova D. A. Ponomarev Thrombophilia identified as a risk factor for thrombogenesis in cancer patients Акушерство, гинекология и репродукция genetic and acquired thrombophilia thrombotic complications anticoagulant therapy circulating antiphospholipid antibodies apa thrombosis risk factors |
| title | Thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| title_full | Thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| title_fullStr | Thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| title_full_unstemmed | Thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| title_short | Thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| title_sort | thrombophilia identified as a risk factor for thrombogenesis in cancer patients |
| topic | genetic and acquired thrombophilia thrombotic complications anticoagulant therapy circulating antiphospholipid antibodies apa thrombosis risk factors |
| url | https://www.gynecology.su/jour/article/view/1003 |
| work_keys_str_mv | AT avvorobev thrombophiliaidentifiedasariskfactorforthrombogenesisincancerpatients AT admakatsariya thrombophiliaidentifiedasariskfactorforthrombogenesisincancerpatients AT vobitsadze thrombophiliaidentifiedasariskfactorforthrombogenesisincancerpatients AT agsolopova thrombophiliaidentifiedasariskfactorforthrombogenesisincancerpatients AT daponomarev thrombophiliaidentifiedasariskfactorforthrombogenesisincancerpatients |